dc.contributor.author | Bisogno, G | |
dc.contributor.author | Minard-Colin, V | |
dc.contributor.author | Jenney, M | |
dc.contributor.author | Ferrari, A | |
dc.contributor.author | Chisholm, J | |
dc.contributor.author | Di Carlo, D | |
dc.contributor.author | Hjalgrim, LL | |
dc.contributor.author | Orbach, D | |
dc.contributor.author | Merks, JHM | |
dc.contributor.author | Casanova, M | |
dc.coverage.spatial | Switzerland | |
dc.date.accessioned | 2023-10-18T14:55:28Z | |
dc.date.available | 2023-10-18T14:55:28Z | |
dc.date.issued | 2023-08-07 | |
dc.identifier | ARTN 4012 | |
dc.identifier | cancers15154012 | |
dc.identifier.citation | Cancers, 2023, 15 (15), pp. 4012 - | |
dc.identifier.issn | 2072-6694 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/6020 | |
dc.identifier.eissn | 2072-6694 | |
dc.identifier.eissn | 2072-6694 | |
dc.identifier.doi | 10.3390/cancers15154012 | |
dc.description.abstract | Maintenance chemotherapy (MC) defines the administration of prolonged relatively low-intensity chemotherapy with the aim of "maintaining" tumor complete remission. This paper aims to report an update of the RMS2005 trial, which demonstrated better survival for patients with high-risk localized rhabdomyosarcoma (RMS) when MC with vinorelbine and low-dose cyclophosphamide was added to standard chemotherapy, and to discuss the published experience on MC in RMS. In the RMS2005 study, the outcome for patients receiving MC vs. those who stopped the treatment remains superior, with a 5-year disease-free survival of 78.1% vs. 70.1% (p = 0.056) and overall survival of 85.0% vs. 72.4% (p = 0.008), respectively. We found seven papers describing MC in RMS, but only one randomized trial that did not demonstrate any advantage when MC with eight courses of trofosfamide/idarubicine alternating with trofosfamide/etoposide has been employed in high-risk RMS. The use of MC showed better results in comparison to high-dose chemotherapy in non-randomized studies, including metastatic patients, and demonstrated feasibility and tolerability in relapsed RMS. Many aspects of MC in RMS need to be investigated, including the best drug combination and the optimal duration. The ongoing EpSSG trial will try to answer some of these questions. | |
dc.format | Electronic | |
dc.format.extent | 4012 - | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | MDPI | |
dc.relation.ispartof | Cancers | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | low-dose chemotherapy | |
dc.subject | maintenance chemotherapy | |
dc.subject | metronomic chemotherapy | |
dc.subject | rhabdomyosarcoma | |
dc.title | Maintenance Chemotherapy for Patients with Rhabdomyosarcoma. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-07-28 | |
dc.date.updated | 2023-10-18T11:30:45Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.3390/cancers15154012 | |
rioxxterms.licenseref.startdate | 2023-08-07 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/37568826 | |
pubs.issue | 15 | |
pubs.organisational-group | ICR | |
pubs.organisational-group | ICR/Primary Group | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials in Children and Young People | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Clinical Trials in children and young people | |
pubs.organisational-group | ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials in Children and Young People/Sarcoma Clinical Trials in Children and Young People (hon.) | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Clinical Trials in children and young people/Sarcoma Clinical Trials in Children and Young People (hon.) | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.3390/cancers15154012 | |
pubs.volume | 15 | |
dc.contributor.icrauthor | Chisholm, Julia | |
icr.provenance | Deposited by Dr Julia Chisholm on 2023-10-18. Deposit type is initial. No. of files: 1. Files: Maintenance Chemotherapy for Patients with Rhabdomyosarcoma.pdf | |